In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria.
Martinez-Turrillas R, Martin-Mallo A, Rodriguez-Diaz S, Zapata-Linares N, Rodriguez-Marquez P, San Martin-Uriz P, Vilas-Zornoza A, Calleja-Cervantes ME, Salido E, Prosper F, et al. Mol Ther Methods Clin Dev. 2022 Jun 9; 25:137-146. Epub 2022 Mar 16.